Skip to main content

Table 4 Enrollment and outcomes in studies using Zuspan or modified Zuspan regimens

From: An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management

 

Enrollment N

Outcomes N (%)

Study

Subjects

Pre-eclampsia

Eclampsia

Affected patella reflex

Respiratorydepression

Oliguria

Skipped dose

Calcium gluconate

Maternal death

All

Due to MgSO4

ZUSPAN

Belfort 1

831

831

0

  

55

  

0

0

Coetzee

345

345

0

 

1

  

1 *

0

0

Deshmukh 2

18

12

6

0

1

0

0

1

0

0

Dommisse 3

11

0

11

0

0

0

  

0

0

Manorot

25

25

0

0

0

0

0

0

0

0

Mundle

147

147

0

   

134

 

0

0

SUBTOTALS

1377

1360

17

0 (0.0)

2 (0.15)

55 (4.0)

13 (0.9)

2 (0.15)

0 (0)

0 (0)

ZUSPAN MODIFIED

Aali

50

46

4

1

  

0

0

0

0

Chowdhury

150

0

150

0

0

0

  

5

0

Chissell

8

8

0

1

0

1

1

 

0

0

Dayicioglu

194

194

0

    

1

0

0

Phuapradit

44

44

0

0

  

0

   

SUBTOTALS

446

292

154

2 (0.5)

0 (0)

1 (0.2)

1 (0.2)

1 (0.2)

5 (1.1)

0 (0)

TOTALS

1823

1652

171

2 (0.01)

2 (0.1)

56 (3.1)

14 (0.8)

3 (0.2)

5 (0.3)

0 (0)

  1. 1 Subjects received either Zuspan or Zuspan modified; 2 Eclamptics received Zuspan regimen; pre-eclamptics received modified Zuspan regimen; 3 Five eclamptics received Zuspan regimen and six received a modified Zuspan regimen; 4 6 stopped treatment due to woman’s request, side effects, oliguria or renal failure, or signs of toxicity and 7 due to provider error or provider preference (Personal communication); * Calcium gluconate administered after a magnesium sulfate dosing error caused respiratory depression.
Back to article page

BMC Pregnancy and Childbirth

ISSN: 1471-2393

Contact us